Understanding how extra copies of chromosome 1q affect cancer growth
Official title: Genomic and functional approaches to characterize Chr1q gains in cancer
Funded at Yale University · NIH-11009510 · Data updated 2026-11-12
This study is looking at how extra pieces of chromosome 1 might play a role in different types of cancer, with the hope of finding new ways to treat the disease and help patients feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | January 18, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $520,332 |
| NIH project number | 5R01CA276666-03 |
| Project ID | NIH-11009510 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with cancers that exhibit 1q aneuploidy, such as certain breast cancers and other malignancies.
✕Less likely to help
Patients whose cancers do not involve chromosome 1q alterations may not benefit from this research.
What this research studies
This research investigates the role of extra copies of the q arm of chromosome 1 in various cancers, a condition known as aneuploidy. It aims to understand how these genetic changes contribute to cancer development and progression, particularly focusing on their potential as targets for treatment. By employing advanced computational and functional approaches, the researchers will explore whether these chromosome gains act like 'addictions' in cancer cells, which could lead to new therapeutic strategies. Patients may benefit from insights that could inform more effective cancer treatments.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that target specific genetic alterations in cancer, potentially improving patient outcomes.
How similar studies have gone: While the concept of targeting aneuploidy in cancer is relatively novel, previous research has shown promise in understanding and manipulating other genetic alterations in cancer treatment.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Sheltzer, Jason — Yale University
- Study coordinator: Sheltzer, Jason
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.